|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Center for Cancer Control and Information
Services, National Cancer Center, . Cancer Registry and Statistics.
March
11–2016
|
|
3
|
Castanon A, Landy R and Sasieni PD: Is
cervical screening preventing adenocarcinoma and adenosquamous
carcinoma of the cervix? Int J Cancer. 139:1040–1045. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sasieni P and Adams J: Changing rates of
adenocarcinoma and adenosquamous carcinoma of the cervix in
England. Lancet. 357:1490–1493. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Galic V, Herzog TJ, Lewin SN, Neugut AI,
Burke WM, Lu YS, Hershman DL and Wright JD: Prognostic significance
of adenocarcinoma histology in women with cervical cancer. Gynecol
Oncol. 125:287–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Park JY, Kim DY, Kim JH, Kim YM, Kim YT
and Nam JH: Outcomes after radical hysterectomy in patients with
early-stage adenocarcinoma of uterine cervix. Br J Cancer.
102:1692–1698. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG,
Lee JH and Bae DS: A comparison of pure adenocarcinoma and squamous
cell carcinoma of the cervix after radical hysterectomy in stage
IB-IIA. Gynecol Oncol. 120:439–443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mabuchi S, Okazawa M, Matsuo K, Kawano M,
Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K and Kimura T:
Impact of histological subtype on survival of patients with
surgically-treated stage IA2-IIB cervical cancer: Adenocarcinoma
versus squamous cell carcinoma. Gynecol Oncol. 127:114–20. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shingleton HM, Bell MC, Fremgen A, Chmiel
JS, Russell AH, Jones WB, Winchester DP and Clive RE: Is there
really a difference in survival of women with squamous cell
carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the
cervix? Cancer. 76 (10 Suppl):1948–1955. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farley JH, Hickey KW, Carlson JW, Rose GS,
Kost ER and Harrison TA: Adenosquamous histology predicts a poor
outcome for patients with advanced-stage, but not early-stage,
cervical carcinoma. Cancer. 97:2196–2202. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lea JS, Coleman RL, Garner EO, Duska LR,
Miller DS and Schorge JO: Adenosquamous histology predicts poor
outcome in low-risk stage IB1 cervical adenocarcinoma. Gynecol
Oncol. 91:558–562. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
dos Reis R, Frumovitz M, Milam MR, Capp E,
Sun CC, Coleman RL and Ramirez PT: Adenosquamous carcinoma versus
adenocarcinoma in early-stage cervical cancer patients undergoing
radical hysterectomy: An outcomes analysis. Gynecol Oncol.
107:458–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mabuchi S, Okazawa M, Kinose Y, Matsuo K,
Fujiwara M, Suzuki O, Morii E, Kamiura S, Ogawa K and Kimura T:
Comparison of the prognoses of FIGO stage I to stage II
adenosquamous carcinoma and adenocarcinoma of the uterine cervix
treated with radical hysterectomy. Int J Gynecol Cancer.
22:1389–1397. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Noh JM, Park W, Kim YS, Kim JY, Kim HJ,
Kim J, Kim JH, Yoon MS, Choi JH, Yoon WS, et al: Comparison of
clinical outcomes of adenocarcinoma and adenosquamous carcinoma in
uterine cervical cancer patients receiving surgical resection
followed by radiotherapy: A multicenter retrospective study (KROG
13-10). Gynecol Oncol. 132:618–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang YT, Wang CC, Tsai CS, Lai CH, Chang
TC, Chou HH, Lee SP and Hong JH: Clinical behaviors and outcomes
for adenocarcinoma or adenosquamous carcinoma of cervix treated by
radical hysterectomy and adjuvant radiotherapy or
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 84:420–427. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rose PG, Java JJ, Whitney CW, Stehman FB,
Lanciano R and Thomas GM: Locally advanced adenocarcinoma and
adenosquamous carcinomas of the cervix compared to squamous cell
carcinomas of the cervix in gynecologic oncology group trials of
cisplatin-based chemoradiation. Gynecol Oncol. 135:208–212. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winer I, Alvarado-Cabrero I, Hassan O,
Ahmed QF, Alosh B, Bandyopadhyay S, Thomas S, Albayrak S, Talukdar
S, Al-Wahab Z, et al: The prognostic significance of histologic
type in early stage cervical cancer-A multi-institutional study.
Gynecol Oncol. 137:474–478. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao L, Wen H, Feng Z, Han X and Wu X:
Distinctive clinicopathologic characteristics and prognosis for
different histologic subtypes of early cervical cancer. Int J
Gynecol Cancer. 29:1244–1251. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen JL, Huang CY, Huang YS, Chen RJ, Wang
CW, Chen YH, Cheng JC, Cheng AL and Kuo SH: Differential clinical
characteristics, treatment response and prognosis of locally
advanced adenocarcinoma/adenosquamous carcinoma and squamous cell
carcinoma of cervix treated with definitive radiotherapy. Acta
Obstet Gynecol Scand. 93:661–668. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Plowman GD, Whitney GS, Neubauer MG, Green
JM, McDonald VL, Todaro GJ and Shoyab M: Molecular cloning and
expression of an additional epidermal growth factor
receptor-related gene. Proc Natl Acad Sci USA. 87:4905–4909. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Q, Zhang R, Yan H, Zhao P, Wu L, Wang
H, Li T and Cao B: Prognostic significance of HER3 in patients with
malignant solid tumors. Oncotarget. 8:67140–67151. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fuchs I, Vorsteher N, Buhler H, Evers K,
Sehouli J, Schaller G and Kümmel S: The prognostic significance of
human epidermal growth factor receptor correlations in squamous
cell cervical carcinoma. Anticancer Res. 27:959–963.
2007.PubMed/NCBI
|
|
23
|
Lee CM, Shrieve DC, Zempolich KA, Lee RJ,
Hammond E, Handrahan DL and Gaffney DK: Correlation between human
epidermal growth factor receptor family (EGFR, HER2, HER3, HER4),
phosphorylated Akt (P-Akt), and clinical outcomes after radiation
therapy in carcinoma of the cervix. Gynecol Oncol. 99:415–421.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
FIGO Committee on Gynecologic Oncology, .
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
Int J Gynaecol Obstet. 125:97–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bartley AN, Washington MK, Colasacco C,
Ventura CB, Ismaila N, Benson AB III, Carrato A, Gulley ML, Jain D,
Kakar S, et al: HER2 testing and clinical decision making in
gastroesophageal adenocarcinoma: Guideline From the College of
American Pathologists, American Society for Clinical Pathology, and
American Society of Clinical Oncology. Arch Pathol Lab Med.
140:1345–1363. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kurman RJ, Carcangiu ML and Herrington CS:
World Health Organization classification of tumours of female
reproductive organs. 4th. Geneva: WHO Press; 2014
|
|
27
|
Ryu SY, Kim MH, Nam BH, Lee TS, Song ES,
Park CY, Kim JW, Kim YB, Ryu HS, Park SY, et al: Intermediate-risk
grouping of cervical cancer patients treated with radical
hysterectomy: A Korean gynecologic oncology group study. Br J
Cancer. 110:278–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim MK, Jo H, Kong HJ, Kim HC, Kim JW, Kim
YM, Song YS, Kang SB, Mok JE and Lee HP: Postoperative nomogram
predicting risk of recurrence after radical hysterectomy for
early-stage cervical cancer. Int J Gynecol Cancer. 20:1581–1386.
2010.PubMed/NCBI
|
|
29
|
Wang H, Zhu L, Lu W, Xu H, Yu Y and Yang
Y: Clinicopathological risk factors for recurrence after
neoadjuvant chemotherapy and radical hysterectomy in cervical
cancer. World J Surg Oncol. 11:3012013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanner B, Hasenclever D, Stern K,
Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer IB,
Gebhard S, et al: ErbB-3 predicts survival in ovarian cancer. J
Clin Oncol. 24:4317–4323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Witton CJ, Reeves JR, Going JJ, Cooke TG
and Bartlett JM: Expression of the HER1-4 family of receptor
tyrosine kinases in breast cancer. J Pathol. 200:290–297. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yi ES, Harclerode D, Gondo M, Stephenson
M, Brown RW, Younes M and Cagle PT: High c-erbB-3 protein
expression is associated with shorter survival in advanced
non-small cell lung carcinomas. Mod Pathol. 10:142–148.
1997.PubMed/NCBI
|
|
34
|
Reschke M, Mihic-Probst D, van der Horst
EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H and
Ullrich A: HER3 is a determinant for poor prognosis in melanoma.
Clin Cancer Res. 14:5188–5197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bae SY, La Choi Y, Kim S, Kim M, Kim J,
Jung SP, Choi MY, Lee SK, Kil WH, Lee JE and Nam SJ: HER3 status by
immunohistochemistry is correlated with poor prognosis in hormone
receptor-negative breast cancer patients. Breast Cancer Res Treat.
139:741–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ledel F, Hallstrom M, Ragnhammar P,
Ohrling K and Edler D: HER3 expression in patients with primary
colorectal cancer and corresponding lymph node metastases related
to clinical outcome. Eur J Cancer. 50:656–662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qian G, Jiang N, Wang D, Newman S, Kim S,
Chen Z, Garcia G, MacBeath G, Shin DM, Khuri FR, et al: Heregulin
and HER3 are prognostic biomarkers in oropharyngeal squamous cell
carcinoma. Cancer. 121:3600–3611. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ema A, Yamashita K, Ushiku H, Kojo K,
Minatani N, Kikuchi M, Mieno H, Moriya H, Hosoda K, Katada N, et
al: Immunohistochemical analysis of RTKs expression identified HER3
as a prognostic indicator of gastric cancer. Cancer Sci.
105:1591–1600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Amin DN, Campbell MR and Moasser MM: The
role of HER3, the unpretentious member of the HER family, in cancer
biology and cancer therapeutics. Semin Cell Dev Biol. 21:944–950.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cancer Genome Atlas Research Network, .
Integrated genomic and molecular characterization of cervical
cancer. Nature. 543:378–384. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jaiswal BS, Kljavin NM, Stawiski EW, Chan
E, Parikh C, Durinck S, Chaudhuri S, Pujara K, Guillory J, Edgar
KA, et al: Oncogenic ERBB3 mutations in human cancers. Cancer Cell.
23:603–617. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karachaliou N, Lazzari C, Verlicchi A,
Sosa AE and Rosell R: HER3 as a therapeutic target in cancer.
BioDrugs. 31:63–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bourillon L, Demontoy S, Lenglet A,
Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H,
Rathat G, Garambois V, et al: Higher anti-tumor efficacy of the
dual HER3-EGFR Antibody MEHD7945a combined with ionizing
irradiation in cervical cancer cells. Int J Radiat Oncol Biol Phys.
106:1039–1051. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Crosbie EJ, Einstein MH, Franceschi S and
Kitchener HC: Human papillomavirus and cervical cancer. Lancet.
382:889–899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pollock NI, Wang L, Wallweber G, Gooding
WE, Huang W, Chenna A, Winslow J, Sen M, DeGrave KA, Li H, et al:
Increased expression of HER2, HER3, and HER2:HER3 heterodimers in
HPV-Positive HNSCC using a novel proximity-based assay:
implications for targeted therapies. Clin Cancer Res. 21:4597–4606.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Brand TM, Hartmann S, Bhola NE, Peyser ND,
Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S,
Duvvuri U, et al: Human papillomavirus regulates HER3 expression in
head and neck cancer: Implications for targeted HER3 therapy in
HPV(+) Patients. Clin Cancer Res. 23:3072–3083. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu JF, Ray-Coquard I, Selle F, Poveda AM,
Cibula D, Hirte H, Hilpert F, Raspagliesi F, Gladieff L, Harter P,
et al: Randomized phase II trial of seribantumab in combination
with paclitaxel in patients with advanced platinum-resistant or
-refractory ovarian cancer. J Clin Oncol. 34:4345–4353. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kogawa T, Yonemori K, Masuda N, Takahashi
S, Takahashi M, Iwase H, Nakayama T, Saeki T, Toyama T, Takano T,
et al: Single agent activity of U3-1402, a HER3-targeting
antibody-drug conjugate, in breast cancer patients: Phase 1 dose
escalation study. J Clin Oncol. 36 (Suppl 15):25122018. View Article : Google Scholar
|
|
49
|
Janne PA, Yu HA, Johnson ML, Steuer CE,
Vigliotti M, Iacobucci C, Chen S, Yu C and Dalila B. Sellami DB;
Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer
Center; Sarah Cannon Research Institute; Winship Cancer Institute
of Emory University; Daiichi Sankyo Inc., : Safety and preliminary
antitumor activity of U3-1402: A HER3-targeted antibody drug
conjugate in EGFR TKI-resistant, EGFRm NSCLC. J Clin Oncol. 37
(Suppl 15):90102019. View Article : Google Scholar
|
